Adaptive resistance to cefiderocol in carbapenem-resistant Acinetobacter baumannii (CRAB): microbiological and clinical issues
Open Access
Abstract
No abstract availableKeywords
All Related Versions
This publication has 17 references indexed in Scilit:
- Real-world clinical outcome of cefiderocol for treatment of multidrug-resistant non-fermenting, gram negative bacilli infections: a case seriesClinical Microbiology and Infection, 2022
- Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of ResistanceAntibiotics, 2022
- Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?The Lancet Microbe, 2021
- Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumanniiAntimicrobial Agents and Chemotherapy, 2021
- New Perspectives on Antimicrobial Agents: CefiderocolAntimicrobial Agents and Chemotherapy, 2021
- Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogensThe Lancet Infectious Diseases, 2021
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trialThe Lancet Infectious Diseases, 2021
- In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative BacteriaAntimicrobial Agents and Chemotherapy, 2020
- Antibiotic combinations that exploit heteroresistance to multiple drugs effectively control infectionNature Microbiology, 2019
- Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysisThe Lancet Infectious Diseases, 2019